-+ 0.00%
-+ 0.00%
-+ 0.00%

There May Be Underlying Issues With The Quality Of Mochida Pharmaceutical's (TSE:4534) Earnings

Simply Wall St·11/18/2026 22:50:08
Listen to the news

Mochida Pharmaceutical Co., Ltd.'s (TSE:4534) stock was strong after they recently reported robust earnings. We did some analysis and think that investors are missing some details hidden beneath the profit numbers.

earnings-and-revenue-history
TSE:4534 Earnings and Revenue History November 18th 2026

Zooming In On Mochida Pharmaceutical's Earnings

As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.

As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.

Mochida Pharmaceutical has an accrual ratio of 0.24 for the year to September 2026. We can therefore deduce that its free cash flow fell well short of covering its statutory profit. Even though it reported a profit of JP¥10.8b, a look at free cash flow indicates it actually burnt through JP¥14b in the last year. It's worth noting that Mochida Pharmaceutical generated positive FCF of JP¥2.8b a year ago, so at least they've done it in the past. Having said that, there is more to the story. We can see that unusual items have impacted its statutory profit, and therefore the accrual ratio.

See our latest analysis for Mochida Pharmaceutical

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Mochida Pharmaceutical.

The Impact Of Unusual Items On Profit

Given the accrual ratio, it's not overly surprising that Mochida Pharmaceutical's profit was boosted by unusual items worth JP¥989m in the last twelve months. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And, after all, that's exactly what the accounting terminology implies. If Mochida Pharmaceutical doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

Our Take On Mochida Pharmaceutical's Profit Performance

Summing up, Mochida Pharmaceutical received a nice boost to profit from unusual items, but could not match its paper profit with free cash flow. For the reasons mentioned above, we think that a perfunctory glance at Mochida Pharmaceutical's statutory profits might make it look better than it really is on an underlying level. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. For example, we've found that Mochida Pharmaceutical has 3 warning signs (2 are concerning!) that deserve your attention before going any further with your analysis.

In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.